Helen S. Garmory
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Helen S. Garmory has a total of 24 co-authors. Here are the top co-authors by number of shared publications:
Katherine A Brown
4 shared publicationsRichard W Titball
4 shared publicationsRichard W. Titball
3 shared publicationsAmit P. Jathoul
Department of Biomedical Sciences, Defence Science and Technology Laboratory, Porton Down, Salisbury SP4 0JQ, UK
2 shared publicationsJane L. Holley
Department of Biomedical Sciences, Defence Science and Technology Laboratory, Porton Down, Salisbury SP4 0JQ, UK
2 shared publicationsKate F Griffin
2 shared publications
Latest Publications
- 1 June 2005
- Published by Elsevier in Advanced Drug Delivery Reviews
- Vol. 57 (9) , 1343-1361
DNA vaccines for biodefence
- 1 June 2005
- Published by Elsevier in Advanced Drug Delivery Reviews
- Vol. 57 (9) , 1343-1361
DNA vaccines for biodefence
- Open Access
- 20 April 2005
- Published by Springer Nature in Genetic Vaccines and Therapy
- Vol. 3 (1) , 3
Evaluation of the VP22 protein for enhancement of a DNA vaccine against anthrax
Background: Previously, antigens expressed from DNA vaccines have been fused to the VP22 protein from Herpes Simplex Virus type I in order to improve efficacy. However, the immune enhancing mechanism of VP22 is poorly understood and initial suggestions that VP22 can mediate intercellular spread have been questioned. Despite this, fusion of VP22 to antigens expressed from DNA vaccines has improved immune responses, particularly to non-secreted antigens. Methods: In this study, we fused the gene for the VP22 protein to the gene for Protective Antigen (PA) from Bacillus anthracis, the causative agent of anthrax. Protective immunity against infection with B. anthracis is almost entirely based on a response to PA and we have generated two constructs, where VP22 is fused to either the N- or the C-terminus of the 63 kDa protease-cleaved fragment of PA (PA63). Results: Following gene gun immunisation of A/J mice with these constructs, we observed no improvement in the anti-PA antibody response generated. Following an intraperitoneal challenge with 70 50% lethal doses of B. anthracis strain STI spores, no difference in protection was evident in groups immunised with the DNA vaccine expressing PA63 and the DNA vaccines expressing fusion proteins of PA63 with VP22. Conclusion: VP22 fusion does not improve the protection of A/J mice against live spore challenge following immunisation of DNA vaccines expressing PA63.
- 20 April 2005
- Published by Springer Nature in Genetic Vaccines and Therapy
- Vol. 3 (1) , 3
Open AccessEvaluation of the VP22 protein for enhancement of a DNA vaccine against anthrax
Background: Previously, antigens expressed from DNA vaccines have been fused to the VP22 protein from Herpes Simplex Virus type I in order to improve efficacy. However, the immune enhancing mechanism of VP22 is poorly understood and initial suggestions that VP22 can mediate intercellular spread have been questioned. Despite this, fusion of VP22 to antigens expressed from DNA vaccines has improved immune responses, particularly to non-secreted antigens. Methods: In this study, we fused the gene for the VP22 protein to the gene for Protective Antigen (PA) from Bacillus anthracis, the causative agent of anthrax. Protective immunity against infection with B. anthracis is almost entirely based on a response to PA and we have generated two constructs, where VP22 is fused to either the N- or the C-terminus of the 63 kDa protease-cleaved fragment of PA (PA63). Results: Following gene gun immunisation of A/J mice with these constructs, we observed no improvement in the anti-PA antibody response generated. Following an intraperitoneal challenge with 70 50% lethal doses of B. anthracis strain STI spores, no difference in protection was evident in groups immunised with the DNA vaccine expressing PA63 and the DNA vaccines expressing fusion proteins of PA63 with VP22. Conclusion: VP22 fusion does not improve the protection of A/J mice against live spore challenge following immunisation of DNA vaccines expressing PA63.
- Open Access
- 1 December 2004
- Published by American Society for Microbiology in Infection and Immunity
- Vol. 72 (12) , 6757-6763
ATP-Binding Cassette Transporters Are Targets for the Development of Antibacterial Vaccines and Therapies
- 1 December 2004
- Published by American Society for Microbiology in Infection and Immunity
- Vol. 72 (12) , 6757-6763
Open AccessATP-Binding Cassette Transporters Are Targets for the Development of Antibacterial Vaccines and Therapies
Efficacy of DNA vaccines expressing the type F botulinum toxin Hc fragment using different promoters
- Open Access
- 16 September 2003
- Published by Springer Nature in Genetic Vaccines and Therapy
- Vol. 1 (1) , 2
DNA vaccines: improving expression of antigens
DNA vaccination is a relatively recent development in vaccine methodology. It is now possible to undertake a rational step-by-step approach to DNA vaccine design. Strategies may include the incorporation of immunostimulatory sequences in the backbone of the plasmid, co-expression of stimulatory molecules, utilisation of localisation/secretory signals, and utilisation of the appropriate delivery system, for example. However, another important consideration is the utilisation of methods designed to optimise transgene expression. In this review we discuss the importance of regulatory elements, kozak sequences and codon optimisation in transgene expression.
- 16 September 2003
- Published by Springer Nature in Genetic Vaccines and Therapy
- Vol. 1 (1) , 2
Open AccessDNA vaccines: improving expression of antigens
DNA vaccination is a relatively recent development in vaccine methodology. It is now possible to undertake a rational step-by-step approach to DNA vaccine design. Strategies may include the incorporation of immunostimulatory sequences in the backbone of the plasmid, co-expression of stimulatory molecules, utilisation of localisation/secretory signals, and utilisation of the appropriate delivery system, for example. However, another important consideration is the utilisation of methods designed to optimise transgene expression. In this review we discuss the importance of regulatory elements, kozak sequences and codon optimisation in transgene expression.
- 11 February 2003
- Published by Elsevier in Microbial Pathogenesis
- Vol. 34 (3) , 115-119
Construction and evaluation of a eukaryotic expression plasmid for stable delivery using attenuated Salmonella
- 11 February 2003
- Published by Elsevier in Microbial Pathogenesis
- Vol. 34 (3) , 115-119
Construction and evaluation of a eukaryotic expression plasmid for stable delivery using attenuated Salmonella
- 1 January 2003
- Published by Taylor & Francis in Journal of Drug Targeting
- Vol. 11 (8-10) , 471-479
The Use of Live Attenuated Bacteria as a Delivery System for Heterologous Antigens
Live attenuated mutants of several pathogenic bacteria have been exploited as potential vaccine vectors for heterologous antigen delivery by the mucosal route. Such live vectors offer the advantage of potential delivery in a single oral, intranasal or inhalational dose, stimulating both systemic and mucosal immune responses. Over the years, a range of strategies have been developed to allow controlled and stable delivery of antigens and improved immunogenicity where required. Most of these approaches have been evaluated in Salmonella vaccine vectors and, as a result, several live attenuated recombinant Salmonella vaccines are now in human clinical trials. In this review, these strategies and their use in the development of a delivery system for the Yersinia pestis V antigen are described.
- 1 January 2003
- Published by Taylor & Francis in Journal of Drug Targeting
- Vol. 11 (8-10) , 471-479
The Use of Live Attenuated Bacteria as a Delivery System for Heterologous Antigens
Live attenuated mutants of several pathogenic bacteria have been exploited as potential vaccine vectors for heterologous antigen delivery by the mucosal route. Such live vectors offer the advantage of potential delivery in a single oral, intranasal or inhalational dose, stimulating both systemic and mucosal immune responses. Over the years, a range of strategies have been developed to allow controlled and stable delivery of antigens and improved immunogenicity where required. Most of these approaches have been evaluated in Salmonella vaccine vectors and, as a result, several live attenuated recombinant Salmonella vaccines are now in human clinical trials. In this review, these strategies and their use in the development of a delivery system for the Yersinia pestis V antigen are described.